Stock listing

LSE:0R2M Regeneron Pharmaceuticals, Inc. Share Price

UK listing (LSE) of Regeneron Pharmaceuticals, Inc. · home listing NASDAQ:REGN

Follow Regeneron Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · LSE:0R2M

$811.46 USD +5.69 (+0.7%)

Close on Oct 27, 2026

Day range
$797.51 – $816.99 USDOct 27, 2026
Volume
198 sharesOct 27, 2026
Regeneron Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:REGN · Home$927.89 USD+109.12 (+13.3%)2,851,725$869.43$935.34$839.08$818.77Close on Oct 30, 2026
B3:REGN3472.24 BRL+5.32 (+7.9%)73472.6272.6271.7666.92Close on Oct 27, 2026
Frankfurt:RGO€826.40 EUR+100.50 (+13.8%)11€738.30€826.40€738.30€725.90Close on Oct 30, 2026
LSE:0R2M$811.46 USD+5.69 (+0.7%)198$816.99$816.99$797.51$805.77Close on Oct 27, 2026
Ticker
LSE:0R2M
Asset type
Stock
Exchange
LSE
Currency
USD

What changed lately

Calls

Replays

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Call

    Fri, Oct 30, 2026 · 8:30 AM ET

    Watch Transcript

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:30 AM ET

    Watch Transcript

  • Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Regeneron Announces Investor Conference Presentations

Nov 2, 2026

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Oct 30, 2026

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Oct 26, 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Oct 25, 2026

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Oct 16, 2026

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Oct 6, 2026

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Oct 1, 2026

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Oct 1, 2026

Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency

Oct 1, 2026

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Oct 1, 2026

All Regeneron Pharmaceuticals, Inc. news

Decks

Regeneron Pharmaceuticals, Inc. on 6ix

News releases
74 in the last 12 months · 369 in all · newest Nov 2, 2026 · oldest 2020
Calls
32 calls with a replay · 32 with a transcript · latest Oct 30, 2026
Decks
64 decks · latest July 2026

Where Regeneron Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:REGN · Home listingNASDAQUnited StatesUSD
gettex:RGOgettexGermanyEUR
LS Exchange:881535LS ExchangeGermanyEUR
Tradegate:RGOTradegateGermanyEUR
BMV:REGNBMVMexicoMXN
B3:REGN34B3BrazilBRL
BOATS:REGNBOATSUnited StatesUSD
Frankfurt:RGOFrankfurtGermanyEUR
LSE:0R2M · This pageLSEUnited KingdomUSD
Lang & Schwarz:881535Lang & SchwarzGermanyEUR
Dusseldorf:RGODusseldorfGermanyEUR
VIE:REGNViennaAustriaEUR
BIVA:REGNBIVAMexicoMXN
Stuttgart:RGOStuttgartGermanyEUR
Milan:1REGNMilanItalyEUR
Munich:RGOMunichGermanyEUR
Turquoise:REGNNTurquoiseUnited KingdomUSD
Xetra:RGOXetraGermanyEUR
EUROTLX:4REGNEUROTLXItalyEUR
BX Swiss:RGOBX SwissSwitzerlandCHF
Hanover:RGOHanoverGermanyEUR
BVL:REGNUSBVLPeruPEN
Hamburg:RGOHamburgGermanyEUR

Log in to ask 6ix AI your own questions about Regeneron Pharmaceuticals, Inc.